Merck wins in drug war with Glenmark


On 7 October, Delhi High Court barred generics manufacturer Glenmark Pharmaceuticals from selling, distributing, marketing and exporting its anti-diabetes drugs Zita and Zitamet. The court found that Glenmark had infringed US-based Merck Sharp & Dohme’s sitagliptin patent used in its anti-diabetes drugs Januvia and Janumet.

You must be a subscriber to read this content, or you can register for free to enjoy the current issue.